Menu

A SIMPLE AND CONVENIENT
SINGLE-TABLET REGIMEN[1–6]

DOVATO is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

A SIMPLE AND CONVENIENT SINGLE-TABLET REGIMEN[1–6]

One tablet, once a day[1]

Can be taken with or without food[1]

No time-of-day restrictions[1]

Few clinically significant drug-drug interactions[*,7]

  • Click to view DDIs

    Few clinically significant drug-drug interactions[7]

    DOVATO has a lower rate of clinically relevant DDIs vs. other single-tablet regimens[7]

    The figure above reports the percentage of potential, observed and currently under monitoring drug-drug interactions for various antiretrovirals (ARVs). 

    Adapted from European AIDS Clinical Society (EACS) Guidelines, 2023[†,‡,7]

    *Contraindicated with fampridine

Choosing a regimen with a favourable DDI profile now can help to mitigate the need of a switch in the future if additional treatments are needed to manage comorbidities.[1,7,8]

PACKAGING MADE FOR LIVING: DOVATO IS NOW AVAILABLE IN A PRACTICAL AND CONVENIENT BLISTER PACK

People living with HIV experiencing HIV-related stigma are 32% less likely to adhere to antiretroviral therapy vs. those not reporting stigma (n=4,053).[§,9,10]

The DOVATO blister pack aims to reduce attention to the person’s medication. Together with indicators for the days of the week, this could help people living with HIV keep their medication on track.

Each box of DOVATO contains 30 tablets, packaged into 5 blister pack cards, which are 
79 mm x 55 mm x 6.7 mm.

Discreet

It’s small - a smaller surface area than a credit card, meaning it can easily fit into your patient’s pocket.

Practical

Helps keep treatment routine on track with indicators for days of the week.

Convenient

With a perforated line, the pack can be torn to make it even smaller, adding more convenience for those weekends away.

Visual representation of DOVATO in the Blister Pack

Efficacy of DOVATO across treatment settings

See data from the relevant randomised controlled trials and real-world evidence

Explore the data

Proven high barrier to resistance in data up to 5 years [11–13]

Explore the data

3TC, lamivudine; ABC, abacavir; AIDS, acquired immune deficiency syndrome; ARV, antiretroviral; BIC, bictegravir; CNS, central nervous system; DDI, drug-drug interaction; DOR, doravirine; DRV, darunavir; DRV/c, DRV co-formulated with cobicistat; DTG, dolutegravir; EACS, European AIDS Clinical Society; FTC, emtricitabine; H2, histamine 2; OCT2, organic cation transporter; PPI, proton-pump inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
*Contraindicated with fampridine and other substrates of the OCT2 with narrow therapeutic windows.[1]
† As defined in EACS guidelines. Includes 43 non-antiretrovirals across cardiovascular drugs, CNS drugs, anti-infective and miscellaneous (e.g., antacids, PPIs, H2 blockers, methadone and St John’s wort). Included in EACS Guidelines as commonly co-prescribed or of particular clinical relevance. Original data source: University of Liverpool HIV drug interaction data.[5]
‡ EACS guidelines state that no additional DDIs are expected when 3TC is added to other antiretroviral therapies including DTG.[5]
§ Association identified in a meta-analysis conducted in 4,053 people living with HIV from a total of 7 studies controlled for potential confounders.[7,8]

References:

  1. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC)
  2. Schneider S et al. Poster presented at the 24th International AIDS Conference. 29 July–2 August 2022. Virtual and Montreal, Canada. EPB147. 
  3. Silva Sombra I et al. Braz J Infect Dis 2021; 25(suppl 1): 101045. 
  4. Calza L et al. J Antimicrob Chemother 2020; 75(11): 3327–3333. 
  5. Tan M et al. HIV Med 2019; 20(9): 634—637.
  6. Yagci Caglayik D et al. Poster presented at European AIDS Clinical Society (EACS). 25—27 October 2017. Milan, Italy. PE912.
  7. European AIDS Clinical Society (EACS) Guidelines. Version 12.0. October 2023.
  8. Devanathan S et al. Clin Pharmacol Ther 2019; 105(6): 1362—1377.[DB1]
  9. Rueda S et al. BMJ Open 2016; 6(7): 1–15.
  10. Rueda S et al. BMJ Open 2016; 6(7): 1–15. (Suppl Appendix)
  11. Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
  12. Ciccullo A et al. JIADS 2021; 1—14.
  13. Taramasso L et al. AIDS Patient Care STDs 2021; 35(9): 342—353.

PM-GB-DLL-WCNT-240008. September 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.